ArticleScientific reports2025
Nationwide longitudinal analysis of COVID-19 hospitalisation burden in immunocompromised patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Increased In-Hospital Mortality in Immunocompromised Individuals Hospitalized With COVID-19 During the Global Pandemic: A Multinational Cohort Study in the EuCARE Project.The Journal of infectious diseases · 2026Article
- Death and ICU Admission Associated with Sars-Cov-2 Variants in Immunocompromised Hospitalised Individuals: A National Observational Study.Infectious diseases and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has caused over 7 million deaths worldwide, with age, underlying conditions, and immunosuppression increasing the incidence of severe outcomes. Despite vaccination, immunocompromised (IC) individuals show lower vaccine response, probably leading to more breakthrough infections. The objective of our study was to evaluate the overall occurrence of intensive care admission and/or death during hospitalisation, stratified by COVID-19 severity and immunological status (IC vs. non-IC individuals). Our study used a nationwide database to compare COVID-19 hospitalisations and outcomes in IC versus non-immunocompromised individuals (non-IC). This is a longitudinal cohort study analysed de-identified COVID-19 data from Brazil's DATASUS system (02 March 2020-31 December 2023). The study included 361,898 subjects, identifying 7484 (2.07%) IC individuals. IC individuals showed higher rates of chronic liver, neurological, and lung diseases, while non-IC individuals had higher obesity rates. Intensive care unit (ICU) admissions (42.6% vs. 38.5%) and mortality (51.1% vs. 35.9%) were greater in IC compared to non-IC individuals. Therefore, IC individuals consistently experienced more ICU admissions and higher mortality across the COVID-19 pandemic years (odds ratios rising from 1.68 in 2020 to 2.39 in 2023), influenced by the prevalence of SARS-Cov-2 variants. Our study shows higher morbidity and mortality in IC individuals during the COVID-19 pandemic, underscoring the need for targeted strategies like early interventions, reinforcing the need for sustained surveillance, targeted vaccination strategies, and prioritised care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.